Quinn GTM brain

Quinn provides biopharma teams with research, analysis and design for drug development and portfolio decisions.

category

Biopharma research and strategy services

market profile

  • text: Drug development teams must synthesize scientific and commercial evidence across multiple stages and disciplines.
  • text: AI research environments and specialized consultants compete for parts of the R&D decision workflow.

personas

  • title: Head of discovery or translational science
    pains:
    • Prioritizing targets with incomplete evidence
    • Finding computational design capacity without slowing research
  • title: Clinical development leader
    pains:
    • Choosing a patient population and next study under uncertainty
    • Making evidence and assumptions clear to decision makers
  • title: Biopharma business development or portfolio leader
    pains:
    • Comparing assets for licensing and allocation
    • Combining scientific due diligence with commercial scenarios

icp

  • text: Biotech and pharmaceutical companies with active drug programs spanning discovery through commercialization; company size is not specified.
  • text: Teams facing a specific target, trial, portfolio or licensing decision and needing external analytical capacity.

message pillars

  • text: Engage a cross-functional team for a concrete decision.
  • text: Receive work quickly after approving its scope.
  • text: Retain project IP and keep it out of model training.

objections

  • objection: Can we trust a rapid analysis for a high-stakes program?
    response: Review the underlying work, evidence, methods and assumptions with your scientific team before using it in a decision.
  • objection: Will sensitive project data be reused?
    response: Quinn says project data is not used for training and offers security documentation and a HIPAA BAA.

competitors

  • name: BenchSci
    website: https://www.benchsci.com/platform
    why: AI research environment for target validation, evidence and preclinical R&D.
  • name: Scitaris
    website: https://scitaris.com/
    why: Biopharma strategy consulting for target selection, clinical design and portfolios.
  • name: IQVIA
    website: https://www.iqvia.com/solutions/research-and-development/consulting
    why: R&D consulting across clinical planning and regulatory strategy.

influencers

  • name: Daniel Gomari
    url: https://www.ycombinator.com/companies/quinn
    why: Founder and CEO with computational biology background.

keywords

  • biopharma portfolio strategy
  • drug target assessment
  • clinical trial design consulting
  • biotech licensing due diligence
  • computational molecule design
  • biopharma market access strategy

voice

  • scientific and evidence-oriented
  • direct and decision-focused
  • reassuring about security

signals

  • text: An asset is approaching a patient population or trial design decision.
  • text: A company is evaluating a licensing opportunity or reprioritizing its portfolio.

pricing

model: unknown

motion

sales_led

channels

  • website
  • LinkedIn

confidence

medium

Founders

  • name: Daniel Gomari
    title: Founder/CEO
    role: CEO
    bio: Daniel Gomari is the founder and CEO of Quinn. A Stanford postdoc and PhD in Computational Biology, his work spanned ML for drug repurposing across cancer and metabolic disease, and multi-omics studies on aging and lifespan extension. He built Quinn after watching the pharma industry make billion-dollar R&D decisions on intuition and slide decks instead of computational evidence.

Back to YC companies